6/14
08:10 am
sgmt
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Medium
Report
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
6/10
08:03 am
sgmt
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat [Yahoo! Finance]
Medium
Report
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat [Yahoo! Finance]
6/10
08:00 am
sgmt
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
Medium
Report
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
6/7
02:02 pm
sgmt
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $48.00 price target on the stock.
Low
Report
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $48.00 price target on the stock.
6/7
11:08 am
sgmt
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Low
Report
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
6/6
05:03 am
sgmt
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024 [Yahoo! Finance]
Medium
Report
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024 [Yahoo! Finance]
6/6
05:00 am
sgmt
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
Low
Report
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
5/24
12:18 pm
sgmt
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $48.00 price target on the stock.
Low
Report
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $48.00 price target on the stock.
5/24
08:04 am
sgmt
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Low
Report
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
5/16
08:15 am
sgmt
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Neutral
Report
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
5/16
08:14 am
sgmt
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $27.00 to $23.00. They now have a "buy" rating on the stock.
Neutral
Report
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $27.00 to $23.00. They now have a "buy" rating on the stock.
5/16
08:14 am
sgmt
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024 [Yahoo! Finance]
Low
Report
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024 [Yahoo! Finance]
5/16
08:00 am
sgmt
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
Low
Report
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
5/15
08:20 am
sgmt
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]
Low
Report
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]
5/15
08:00 am
sgmt
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Low
Report
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
5/7
08:00 am
sgmt
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
Low
Report
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
5/6
08:13 am
sgmt
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer [Yahoo! Finance]
Medium
Report
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer [Yahoo! Finance]
5/6
08:00 am
sgmt
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
Medium
Report
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
5/2
07:08 am
sgmt
Sagimet Biosciences Inc. (NASDAQ: SGMT) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $32.00 price target on the stock.
Low
Report
Sagimet Biosciences Inc. (NASDAQ: SGMT) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $32.00 price target on the stock.
4/26
12:26 pm
sgmt
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity [Seeking Alpha]
Low
Report
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity [Seeking Alpha]
4/22
08:13 am
sgmt
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 [Yahoo! Finance]
Low
Report
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 [Yahoo! Finance]
4/22
08:00 am
sgmt
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
Low
Report
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
4/4
08:10 am
sgmt
Sagimet Biosciences Insiders Added US$821.7k Of Stock To Their Holdings [Yahoo! Finance]
Low
Report
Sagimet Biosciences Insiders Added US$821.7k Of Stock To Their Holdings [Yahoo! Finance]
3/27
04:09 pm
sgmt
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat [Yahoo! Finance]
Medium
Report
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat [Yahoo! Finance]
3/27
04:01 pm
sgmt
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
Medium
Report
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat